Mumbai, Nov 12: Just as the country braces itself for the second wave of Swine flu expected to hit during the winter, pharmaceutical major Cipla released a new variant of anti-H1N1 drug Oseltamivir, called Antiflu.
"We have launched Oseltamivir brand, called Antiflu, which is the only flu medicine from India to be prequalified by World Health Organisation," Cipla's Chairman and Managing Director, Y K Hamied announced on Wednesday, Nov 11.
Cipla informed that 10 capsules of Antiflu or 75 ml syrup of the antiviral drug will be priced at Rs 475. These drugs will be made available across the country.
With this release, Cipla became the sixth pharmaceutical firm to launch its version of Oseltamivir also known as Tamiflu, which is the only drug known to work against H1N1 virus.
Oseltamivir or Tamiflu manufactured by Roche, a Swiss pharmaceuticals group has treated over 42 million people across the world.